Cardiac risk and schizophrenia.

作者: Erin M. MacKenzie , Vikram K. Yeragani , Ripu Jindal , Glen B. Baker

DOI:

关键词: Atypical antipsychoticAntipsychoticSudden deathAbsolute risk reductionPopulationSudden cardiac deathPediatricsPsychiatryMedicineQT intervalHeart disease

摘要: Sudden cardiac death, which is defined as death from a cause within short time (minutes to hours) after symptoms initially appear, often without warning, major public health problem, accounting for about 10% of all natural deaths and over 50% coronary mortality. Most individuals who die sudden have no history heart disease. 1 Patients with schizophrenia been reported be 3 times likely experience unexpected than the general population, 2 although specific aspects contributing this increased risk remain unclear. Different factors related underlying pathology, antipsychotic medications lifestyle (e.g., smoking, neglect health, poor diet decreased access care services) may contribute mortality in these patients. A recent study found that patients received medication were 1.4 more unexpectedly drug free. However, did not include taking any atypical (secondgeneration) drugs. Cases subjects drugs, but review drugs indicates they are generally safe. 4 The situation regard confounded by fact there an excess even when treated number other co-administered also associated QTc prolongation, 5 discussed below. measures shown predict arrhythmias non-diseased observed schizophrenia. For example, prolonged QT interval (increased taken recover previous contraction) or (QT corrected rate) has factor such events,

参考文章(41)
Charles M. Beasley, Sara Kollack-Walker, Joerg Czekalla, Cardiac safety parameters of olanzapine : Comparison with other atypical and typical antipsychotics The Journal of Clinical Psychiatry. ,vol. 62, pp. 35- 40 ,(2001)
Pierre Chue, Raphael Cheung, The impact of weight gain associated with atypical antipsychotic use in schizophrenia Acta Neuropsychiatrica. ,vol. 16, pp. 113- 123 ,(2004) , 10.1111/J.0924-2708.2004.00067.X
ISRAEL NACHSHON, Hemispheric dysfunctioning in schizophrenia. Journal of Nervous and Mental Disease. ,vol. 168, pp. 241- 242 ,(1980) , 10.1097/00005053-198004000-00009
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M.-R. Taskinen, L. Groop, Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome Diabetes Care. ,vol. 24, pp. 683- 689 ,(2001) , 10.2337/DIACARE.24.4.683
G. W. Eschweiler, M. Bartels, G. Längle, B. Wild, I. Gaertner, M. Nickola, Heart-Rate Variability (HRV) in the ECG Trace of Routine EEGs: Fast Monitoring for the Anticholinergic Effects of Clozapine and Olanzapine? Pharmacopsychiatry. ,vol. 35, pp. 96- 100 ,(2002) , 10.1055/S-2002-31520
Claudia St??llberger, Johannes O. Huber, Josef Finsterer, Antipsychotic drugs and QT prolongation. International Clinical Psychopharmacology. ,vol. 20, pp. 243- 251 ,(2005) , 10.1097/01.YIC.0000166405.49473.70
P T Nguyen, M M Scheinman, J Seger, Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation. ,vol. 74, pp. 340- 349 ,(1986) , 10.1161/01.CIR.74.2.340
Thomas Rechlin, Georg Beck, Maria Weis, Wolfgang P. Kaschka, Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacology. ,vol. 135, pp. 338- 341 ,(1998) , 10.1007/S002130050520
Ung Gu Kang, Jun Soo Kwon, Yong Min Ahn, Sun Ju Chung, Jee Hyun Ha, Young Jin Koo, Yong Sik Kim, Electrocardiographic abnormalities in patients treated with clozapine. The Journal of Clinical Psychiatry. ,vol. 61, pp. 441- 446 ,(2000) , 10.4088/JCP.V61N0609
Vikram K. Yeragani, Ravi Nadella, Brian Hinze, Suneetha Yeragani, V.C. Jampala, Nonlinear measures of heart period variability: decreased measures of symbolic dynamics in patients with panic disorder. Depression and Anxiety. ,vol. 12, pp. 67- 77 ,(2000) , 10.1002/1520-6394(2000)12:2<67::AID-DA2>3.0.CO;2-C